Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04878691 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-04878691 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-04878691 3mg | DRUG | Oral solution, 3mg, twice weekly, 2 weeks |
| PF-04878691 6mg | DRUG | Oral solution, 6mg, twice weekly, 2 weeks |
| PF-04878691 9mg | DRUG | Oral solution, 9mg, twice weekly, 2 weeks |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18-55, inclusive. * Body Mass Index (BMI) of 18-30 kg/m2; total body weight \>50kg (110lbs). Exclusion Criteria: * Pregnant or nursing females. * Females of child-bearing potential. * Evidence of history of clinically s...
PF-04878691 is an investigational small molecule antiviral developed by Pfizer, Inc. for hepatitis C virus infection. It is a Phase 1 candidate that has been studied in a single completed clinical trial. It is not an approved medicine and remains in early clinical development.
PF-04878691 was studied for the treatment of hepatitis C virus infection, an infectious disease of the liver. The only recorded trial enrolled healthy adult volunteers rather than patients with chronic hepatitis C, so the program was evaluated in an early-stage setting. It is not approved for any use.
PF-04878691 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound. No partner or licensing arrangement for this asset is part of the public record for the program.
PF-04878691 is in Phase 1 development. Its single clinical trial, NCT00810758, has been completed, and no active trials of the compound are ongoing. Because it has only completed early Phase 1 testing, PF-04878691 is investigational and has not received FDA approval for hepatitis C virus infection.
PF-04878691 has been studied in one clinical trial, NCT00810758, titled a multiple oral dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04878691. The Phase 1 trial enrolled 24 healthy volunteers in the United States, used a randomized, double-blind design, and has completed.